Scale-Up & Capacity

USP and DSP scale-up, new plants, CDMO capacity, reshoring and the policy behind it.

15 pieces

Brief

Minaris adds a dedicated viral vectors business unit, effective 1 October 2026

The CGT CDMO now runs cell therapies, viral vectors and advanced testing as three business units. Viral vector CDMO services are centralized at its Philadelphia site.

14 Oct 2026

Research

ATF vs TFF in perfusion: what the filter holds back, why it fouls and how it scales

2 Oct 2026

Research

Fed-batch vs perfusion: what the numbers say on output, plant size and cost

1 Oct 2026

Brief

Preprint: Alginate microencapsulation curbs stem-cell islet clumping in bioreactors

1 Oct 2026

Brief

AGC Biologics to Scale Up Flen Health’s Recombinant Wound-Care Enzymes

1 Oct 2026

Research

Perfusion, explained: three flows, one balance, and where the product goes

29 Sep 2026

Research

From 2 L to 2,000 L: what actually breaks when you scale a CHO process

27 Sep 2026

Brief

AGC Biologics commits half of Yokohama’s mammalian capacity before the site opens

26 Sep 2026

Brief

FDA PreCheck pilot: Fujifilm Holly Springs and Cellares say they are among seven

26 Sep 2026

Brief

Samsung Biologics’ KRW 3 trillion rights offering: about 90% is earmarked for PolyPeptide

26 Sep 2026